Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab

2.1 Obinutuzumab (Gazyvaro, Roche) with bendamustine followed by obinutuzumab maintenance has a marketing authorisation for 'the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 Obinutuzumab costs £3,312 per 1,000 mg/40 ml concentrate for solution for infusion vial (excluding VAT; BNF online, accessed May 2020).

2.4 The company has a commercial arrangement. This makes obinutuzumab with bendamustine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.